That result repositioned semaglutide in the pharmacological landscape the compound is no longer primarily framed as a metabolic-disease agent, but as a cardiovascular-outcomes agent whose effects extend beyond glycemic control
PLos ONE 6 6 , e21486 (2011)
The high heterogeneity of the results likely responds to different baseline A1c, variable rates of obesity, as well as different titration protocols to adjust insulin doses
Gradually tapering the dosage, under the guidance of a healthcare professional, can help mitigate these rebound effects
That can look like persistent low energy, trouble building or holding onto muscle, slower recovery after exercise, stubborn weight gain around the midsection, restless or unrefreshing sleep, or a general sense of not feeling like yourself
No application, claim, or representation extends beyond controlled research examination